ALPN News and Press, Alpine Immune Sciences Inc. From 03/01/22

Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune and inflammatory diseases, today announced that members of its management team will participate at the following investor con...

Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune and inflammatory diseases, today announced that members of its management team will present at the following investor confere...

Alpine Immune Sciences (NASDAQ:ALPN) gains 7.7% premarket after announcing an exclusive license and collaboration agreement with Horizon Therapeutics (NASDAQ:HZNP) for the development and commercialization of up to four preclinical candidates generated from Alpine’s unique di...

Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune and inflammatory diseases, today announced the company will participate in a fireside chat at the 4th Annual Evercore ISI Hea...

Alpine Immune Sciences (NASDAQ:ALPN): Q3 GAAP EPS of -$0.55 misses by $0.56. Revenue of $8.52M (+346.1% Y/Y) misses by $12.67M. Press Release For further details see: Alpine Immune Sciences EPS misses by $0.56, misses on revenue

- Recent private placement enables expansion and acceleration of development plans across the portfolio - - Plenary presentation for ALPN-303 at the American College of Rheumatology Convergence 2021 Annual Meeting highlighting best in class potential - Alpine Immune ...

- ALPN-303 demonstrates superior immunomodulatory activity and efficacy in preclinical models - - Phase 1 study to begin Q4 2021 - Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company, today announced a presentation in a Plenary...

Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory diseases, today announced it has entered into a definitive securities purchase agreement for the sale of common s...

Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory diseases, today announced that members of its management team will present at the following investor conferences ...

The following slide deck was published by Alpine Immune Sciences, Inc. in conjunction with this event. For further details see: Alpine Immune Sciences (ALPN) Investor Presentation